Pierre Miossec

List of Publications by Year in Descending Order

196 papers	13,286 citations	56 h-index	113 g-index
215 ext. papers	15,194 ext. citations	7.1 avg, IF	7.1 L-index

#	Paper	IF	Citations
196	Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.. *Frontiers in Immunology*, **2022**, 13, 820046	8.4	1
195	Synoviocytes from pigmented villonodular synovitis are less sensitive to cadmium-induced cell death than synoviocytes from rheumatoid arthritis.. *Scientific Reports*, **2022**, 12, 3832	4.9	0
194	The Th17 Pathway in Vascular Inflammation: Culprit or Consort?. *Frontiers in Immunology*, **2022**, 13, 888763	8.4	3
193	The role of B cells and their interactions with stromal cells in the context of inflammatory autoimmune diseases.. *Autoimmunity Reviews*, **2022**, 103098	13.6	0
192	Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production.. *Journal of Autoimmunity*, **2022**, 130, 102831	15.5	0
191	Addition of Fibroblast-Stromal Cell Markers to Immune Synovium Pathotypes Better Predicts Radiographic Progression at 1 Year in Active Rheumatoid Arthritis. *Frontiers in Immunology*, **2021**, 12, 778480	8.4	0
190	Impact of Host Immune Status on Discordant Anti-SARS-CoV-2 Circulating B Cell Frequencies and Antibody Levels. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
189	Local and systemic effects of IL-17 in joint inflammation: a historical perspective from discovery to targeting. *Cellular and Molecular Immunology*, **2021**, 18, 860-865	15.4	13
188	Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. *Cellular and Molecular Immunology*, **2021**, 18, 1644-1651	15.4	5
187	Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis. *Current Opinion in Rheumatology*, **2021**, 33, 1-7	5.3	5
186	Importance of lymphocyte-stromal cell interactions in autoimmune and inflammatory rheumatic diseases. *Nature Reviews Rheumatology*, **2021**, 17, 550-564	8.1	5
185	Gastroenterological safety of IL-17 inhibitors: a systematic literature review. *Expert Opinion on Drug Safety*, **2021**, 1-17	4.1	2
184	Key points to consider for an improved detection and characterization of cryoglobulins. *Autoimmunity Reviews*, **2021**, 20, 102948	13.6	
183	Contribution of Hepatitis C Infection to a Large Cohort of Cryoglobulin-Positive Patients: Detection and Characteristics. *Frontiers in Immunology*, **2020**, 11, 1183	8.4	3
182	Joint Destruction Is Associated With All Types of Cardiovascular Events in French Rheumatoid Patients: A Real-Life Study With Very Long Follow-Up. *Frontiers in Medicine*, **2020**, 7, 556086	4.9	1
181	Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation. *European Journal of Rheumatology*, **2020**, 7, S97-S98	1.7	8
180	Evolving concepts of the pathogenesis of rheumatoid arthritis with focus on the early and late stages. *Current Opinion in Rheumatology*, **2020**, 32, 57-63	5.3	23

179	Interleukin-17 and lupus: enough to be a target? For which patients?. *Lupus*, **2020**, 29, 6-14	2.6	16
178	Reply. *Arthritis and Rheumatology*, **2020**, 72, 1956-1957	9.5	
177	IgG subclasses in cryoglobulins: link to composition and clinical manifestations. *Arthritis Research and Therapy*, **2020**, 22, 267	5.7	0
176	Synergistic Interaction Between High Bioactive IL-17A and Joint Destruction for the Occurrence of Cardiovascular Events in Rheumatoid Arthritis. *Frontiers in Immunology*, **2020**, 11, 1998	8.4	3
175	Reduced skeletal muscle independently predicts 1-year aggravated joint destruction in patients with rheumatoid arthritis. *Therapeutic Advances in Musculoskeletal Disease*, **2020**, 12, 1759720X20946220	3.8	3
174	Biological Applications and Toxicity Minimization of Semiconductor Quantum Dots. *Trends in Biotechnology*, **2020**, 38, 163-177	15.1	33
173	High oligoclonality of immunoglobulins in SARS-CoV2 positive patients. *Annals of the Rheumatic Diseases*, **2020**,	2.4	1
172	The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. *Nature Reviews Rheumatology*, **2019**, 15, 747-757	8.1	45
171	Systemic effects of IL-17 in inflammatory arthritis. *Nature Reviews Rheumatology*, **2019**, 15, 491-501	8.1	49
170	Infliximab Induced a Dissociated Response of Severe Periodontal Biomarkers in Rheumatoid Arthritis Patients. *Journal of Clinical Medicine*, **2019**, 8,	5.1	11
169	Cryoglobulins Today: Detection and Immunologic Characteristics of 1,675 Positive Samples From 13,439 Patients Obtained Over Six Years. *Arthritis and Rheumatology*, **2019**, 71, 1904-1912	9.5	11
168	Two phase kinetics of the inflammatory response from hepatocyte-peripheral blood mononuclear cell interactions. *Scientific Reports*, **2019**, 9, 8378	4.9	5
167	IL-17 and TNF-□ co-operation contributes to the proinflammatory response of hepatic stellate cells. *Clinical and Experimental Immunology*, **2019**, 198, 111-120	6.2	10
166	Activation of the Peroxisome Proliferator-Activated Receptor □ Coactivator 1□/NFATc1 Pathway in Circulating Osteoclast Precursors Associated With Bone Destruction in Rheumatoid Arthritis. *Arthritis and Rheumatology*, **2019**, 71, 1252-1264	9.5	9
165	Additive or Synergistic Interactions Between IL-17A or IL-17F and TNF or IL-1□ Depend on the Cell Type. *Frontiers in Immunology*, **2019**, 10, 1726	8.4	16
164	Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). *Ageing Research Reviews*, **2019**, 55, 100946	12	49
163	Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an Co-culture Model With Immune Cells and Synoviocytes. *Frontiers in Immunology*, **2019**, 10, 2992	8.4	4
162	Cryoglobulins: An update on detection, mechanisms and clinical contribution. *Autoimmunity Reviews*, **2018**, 17, 457-464	13.6	35

161	Synergistic effect of interleukin-17 and tumour necrosis factor-α on inflammatory response in hepatocytes through interleukin-6-dependent and independent pathways. *Clinical and Experimental Immunology*, **2018**, 193, 221-233	6.2	20
160	Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. *Annals of the Rheumatic Diseases*, **2018**, 77, 523-532	2.4	123
159	Inflammation in 2017: Connectivity to other fields brings new ideas. *Nature Reviews Rheumatology*, **2018**, 14, 65-66	8.1	1
158	Differential effects of TNF-α and IL-1β on the control of metal metabolism and cadmium-induced cell death in chronic inflammation. *PLoS ONE*, **2018**, 13, e0196285	3.7	19
157	Live-stream characterization of cadmium-induced cell death using visible CdTe-QDs. *Scientific Reports*, **2018**, 8, 12614	4.9	7
156	Réactivation de la tuberculose au cours des traitements par inhibiteurs du TNF : compréhension et prévention. *Bulletin De L'Academie Nationale De Medecine*, **2018**, 202, 321-329	0.1	
155	Cibles des biothérapies au cours des maladies inflammatoires. *Bulletin De L'Academie Nationale De Medecine*, **2018**, 202, 1917-1926	0.1	
154	Blockade of Store-Operated Calcium Entry Reduces IL-17/TNF Cytokine-Induced Inflammatory Response in Human Myoblasts. *Frontiers in Immunology*, **2018**, 9, 3170	8.4	9
153	IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels. *Frontiers in Medicine*, **2018**, 5, 364	4.9	64
152	Is undifferentiated spondyloarthritis a discrete entity? A debate. *Autoimmunity Reviews*, **2018**, 17, 29-32	13.6	7
151	IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. *Autoimmunity Reviews*, **2018**, 17, 1176-1185	13.6	30
150	Selected cytokine pathways in rheumatoid arthritis. *Seminars in Immunopathology*, **2017**, 39, 365-383	12	147
149	Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. *RMD Open*, **2017**, 3, e000284	5.9	59
148	Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritis. *Scientific Reports*, **2017**, 7, 2415	4.9	19
147	PUMA gene delivery to synoviocytes reduces inflammation and degeneration of arthritic joints. *Nature Communications*, **2017**, 8, 146	17.4	18
146	Effects of Interleukin 17 on the cardiovascular system. *Autoimmunity Reviews*, **2017**, 16, 984-991	13.6	67
145	Th17 Cells **2017**, 395-418		
144	Modeling of the effects of IL-17 and TNF-α on endothelial cells and thrombus growth. *Comptes Rendus - Biologies*, **2017**, 340, 456-473	1.4	13

143	Interleukin-25 Produced by Synoviocytes Has Anti-inflammatory Effects by Acting As a Receptor Antagonist for Interleukin-17A Function. *Frontiers in Immunology*, **2017**, 8, 647	8.4	19
142	Regulatory effects of zinc on cadmium-induced cytotoxicity in chronic inflammation. *PLoS ONE*, **2017**, 12, e0180879	3.7	9
141	Early kinetics of serum Interleukine-17A and infarct size in patients with reperfused acute ST-elevated myocardial infarction. *PLoS ONE*, **2017**, 12, e0188202	3.7	9
140	Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). *Aging Clinical and Experimental Research*, **2016**, 28, 1-16	4.8	16
139	IL-17 in Chronic Inflammation: From Discovery to Targeting. *Trends in Molecular Medicine*, **2016**, 22, 230-241	11.5	256
138	Sulfur isotope analysis by MC-ICP-MS and application to small medical samples. *Journal of Analytical Atomic Spectrometry*, **2016**, 31, 1002-1011	3.7	24
137	Progress in the treatment of juvenile dermatomyositis. *Lancet, The*, **2016**, 387, 627-628	40	1
136	Interleukine 17 et l'inflammation chronique : de la découverte au ciblage thérapeutique. *Bulletin De L'Academie Nationale De Medecine*, **2016**, 200, 933-942	0.1	
135	IL-17A and TNF-α Increase the Expression of the Antiapoptotic Adhesion Molecule Amigo-2 in Arthritis Synoviocytes. *Frontiers in Immunology*, **2016**, 7, 254	8.4	11
134	Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an Coculture Model with Immune Cells and Synoviocytes. *Frontiers in Immunology*, **2016**, 7, 509	8.4	5
133	Interaction among activated lymphocytes and mesenchymal cells through podoplanin is critical for a high IL-17 secretion. *Arthritis Research and Therapy*, **2016**, 18, 148	5.7	31
132	A Feedback Loop between Inflammation and Zn Uptake. *PLoS ONE*, **2016**, 11, e0147146	3.7	23
131	Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells. *Clinical and Experimental Immunology*, **2016**, 186, 64-74	6.2	22
130	Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 1420-2	2.4	14
129	Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease. *Annals of the Rheumatic Diseases*, **2016**, 75, 1268-71	2.4	17
128	Increased sensitivity of rheumatoid synoviocytes to Schnurri-3 expression in TNF-α and IL-17A induced osteoblastic differentiation. *Bone*, **2016**, 87, 89-96	4.7	19
127	T-cell clones from Th1, Th17 or Th1/17 lineages and their signature cytokines have different capacity to activate endothelial cells or synoviocytes. *Cytokine*, **2016**, 88, 241-250	4	8
126	Altered dendritic cell functions in autoimmune diseases: distinct and overlapping profiles. *Nature Reviews Rheumatology*, **2016**, 12, 703-715	8.1	59

125	Medical applications of Cu, Zn, and S isotope effects. *Metallomics*, **2016**, 8, 1056-1070	4.5	50
124	A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2015**, 74, 1629-31	2.4	22
123	Differential Effects of IL-17A and TNF- on Osteoblastic Differentiation of Isolated Synoviocytes and on Bone Explants from Arthritis Patients. *Frontiers in Immunology*, **2015**, 6, 151	8.4	37
122	Blockade of bone morphogenetic protein signaling potentiates the pro-inflammatory phenotype induced by interleukin-17 and tumor necrosis factor- combination in rheumatoid synoviocytes. *Arthritis Research and Therapy*, **2015**, 17, 192	5.7	21
121	Zinc and its role in immunity and inflammation. *Autoimmunity Reviews*, **2015**, 14, 277-85	13.6	351
120	Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. *European Journal of Immunology*, **2014**, 44, 339-47	6.1	102
119	Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. *Autoimmunity Reviews*, **2014**, 13, 668-77	13.6	570
118	Introduction: Why is there persistent disease despite aggressive therapy of rheumatoid arthritis? *Arthritis Research and Therapy*, **2014**, 16, 113	5.7	2
117	Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells. *Frontiers in Immunology*, **2014**, 5, 425	8.4	70
116	Rheumatoid arthritis in 2013. Translational medicine in RA: time for change. *Nature Reviews Rheumatology*, **2014**, 10, 74-6	8.1	2
115	Classical and Paradoxical Effects of TNF- on Bone Homeostasis. *Frontiers in Immunology*, **2014**, 5, 48	8.4	207
114	Kinase inhibition in rheumatoid arthritis: a big advance?. *Lancet, The*, **2013**, 381, 429-31	40	4
113	Rheumatoid arthritis: still a chronic disease. *Lancet, The*, **2013**, 381, 884-6	40	27
112	A critical role for immature muscle precursors in myositis. *Nature Reviews Rheumatology*, **2013**, 9, 438-42	8.1	16
111	Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF- on endothelial cells. *Annals of the Rheumatic Diseases*, **2013**, 72, 754-60	2.4	41
110	IL-17 and Th17 Cells in Rheumatoid Arthritis and Other Inflammatory Conditions **2013**, 233-242		
109	Immature muscle precursors are a source of interferon- in myositis: role of Toll-like receptor 3 activation and contribution to HLA class I up-regulation. *Arthritis and Rheumatism*, **2012**, 64, 533-41		49
108	IL-17 and tumour necrosis factor combination induces a HIF-1 dependent invasive phenotype in synoviocytes. *Annals of the Rheumatic Diseases*, **2012**, 71, 1393-401	2.4	53

107	Targeting IL-17 and TH17 cells in chronic inflammation. *Nature Reviews Drug Discovery*, **2012**, 11, 763-76	64.1	829
106	Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. *American Journal of Pathology*, **2012**, 181, 8-18	5.8	407
105	Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis. *Arthritis and Rheumatism*, **2012**, 64, 2147-57		67
104	Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. *Arthritis and Rheumatism*, **2012**, 64, 2499-503		247
103	Interleukin-17 in inflammatory myopathies. *Current Rheumatology Reports*, **2012**, 14, 252-6	4.9	35
102	Combination of IL-17 and TNF induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. *Annals of the Rheumatic Diseases*, **2012**, 71, 768-76	2.4	97
101	Treatment with etanercept of autoimmune hepatitis associated with rheumatoid arthritis: an open label proof of concept study. *Annals of the Rheumatic Diseases*, **2012**, 71, 1423-4	2.4	8
100	IL-17 and TH17 Cells in Human Rheumatoid Arthritis **2011**, 411-420		0
99	Biomarqueurs et m decine personnalis e au cours de la polyarthrite rhumato de : vers un changement historique. *Revue Du Rhumatisme (Edition Francaise)*, **2011**, 78, S154-S156	0.1	
98	Esophageal dysmotility associated with systemic sclerosis: a high-resolution manometry study. *Ecological Management and Restoration*, **2011**, 24, 299-304	3	41
97	IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. *Annals of the Rheumatic Diseases*, **2011**, 70, 341-8	2.4	50
96	Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. *Annals of the Rheumatic Diseases*, **2011**, 70, 727-32	2.4	126
95	Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. *Annals of the Rheumatic Diseases*, **2011**, 70, 1713-8	2.4	31
94	Importance of correlation between gene expression levels: application to the type I interferon signature in rheumatoid arthritis. *PLoS ONE*, **2011**, 6, e24828	3.7	48
93	Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. *Annals of the Rheumatic Diseases*, **2010**, 69, 1562-7	2.4	36
92	FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. *Annals of the Rheumatic Diseases*, **2010**, 69, 755-60	2.4	30
91	Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. *Arthritis Research and Therapy*, **2010**, 12, R143	5.7	34
90	Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis. *Joint Bone Spine*, **2010**, 77, 297-305	2.9	29

89	Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. *Arthritis and Rheumatism*, **2010**, 62, 2144-51		56
88	Biomarqueurs prédictifs de la réponse aux anti-TNF alpha dans la polyarthrite rhumatoïde. *Revue Du Rhumatisme (Edition Francaise)*, **2010**, 77, 448-457	0.1	
87	Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression. *PLoS ONE*, **2010**, 5, e13416	3.7	57
86	Chemokines and dendritic cells in inflammatory myopathies. *Annals of the Rheumatic Diseases*, **2009**, 68, 300-4	2.4	14
85	Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. *Journal of Immunology*, **2009**, 182, 3112-20	5.3	128
84	Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2009**, 68, 1197-200	2.4	20
83	Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus. *Journal of Virology*, **2009**, 83, 6048-66	6.6	11
82	Diseases that may benefit from manipulating the Th17 pathway. *European Journal of Immunology*, **2009**, 39, 667-9	6.1	18
81	IL-17 and Th17 cells in human inflammatory diseases. *Microbes and Infection*, **2009**, 11, 625-30	9.3	187
80	Interleukin-17 and type 17 helper T cells. *New England Journal of Medicine*, **2009**, 361, 888-98	59.2	1095
79	Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. *Cytokine*, **2009**, 46, 297-301	4	44
78	IL-17 inhibits human Th1 differentiation through IL-12R beta 2 downregulation. *Cytokine*, **2009**, 48, 226-30	3	38
77	IL-17 as a future therapeutic target for rheumatoid arthritis. *Nature Reviews Rheumatology*, **2009**, 5, 549-53	8.2	220
76	Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?. *Arthritis Research and Therapy*, **2009**, 11, 246	5.7	25
75	IL-17 and Th17 cells, key players in arthritis **2009**, 89-101		1
74	IL-17 and Th17 cells in rheumatoid arthritis **2009**, 175-184		
73	Physiopathology of haemophilic arthropathy. *Haemophilia*, **2008**, 14 Suppl 4, 3-9	3.3	102
72	Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium. *Arthritis Research and Therapy*, **2008**, 10 Suppl 1, S2	5.7	24

71	IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. *Journal of Immunology*, **2008**, 180, 655-63	5.3	111
70	IL-17 and its Receptor Complex as Therapeutic Targets in Arthritis. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*, **2008**, 8, 247-251		
69	Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. *Biologics: Targets and Therapy*, **2008**, 2, 663-9	4.4	19
68	Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. *Arthritis and Rheumatism*, **2008**, 58, 1258-63		49
67	Interleukin-17 in fashion, at last: ten years after its description, its cellular source has been identified. *Arthritis and Rheumatism*, **2007**, 56, 2111-5		104
66	A rapid semi automated method for DNA extraction from dried-blood spots: application to the HLA-DR shared epitope analysis in rheumatoid arthritis. *Journal of Immunological Methods*, **2007**, 328, 220-5	2.5	3
65	Cytokine response in inflammatory myopathies. *Current Rheumatology Reports*, **2007**, 9, 286-90	4.9	14
64	The role of T cells in rheumatoid arthritis: new subsets and new targets. *Current Opinion in Rheumatology*, **2007**, 19, 284-8	5.3	131
63	IL-17A versus IL-17F induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in AGS gastric adenocarcinoma cells. *Cytokine*, **2007**, 38, 157-64	4	43
62	Cytokines and Autoimmune Diseases. *Methods in Pharmacology and Toxicology*, **2007**, 233-257	1.1	1
61	Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. *Arthritis and Rheumatism*, **2006**, 54, 2109-18		40
60	New regulatory rules for clinical trials in the United States and the European Union: key points and comparisons. *Arthritis and Rheumatism*, **2006**, 54, 3735-40		3
59	Novel aspects on the contribution of T cells and dendritic cells in the pathogenesis of myositis. *Autoimmunity*, **2006**, 39, 171-6	3	9
58	The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. *Annals of the Rheumatic Diseases*, **2006**, 65, 342-7	2.4	58
57	Immunopathologie de la polyarthrite rhumato□de. *EMC - Appareil Locomoteur*, **2006**, 1, 1-8		
56	The association between periodontal disease and joint destruction in rheumatoid arthritis extends the link between the HLA-DR shared epitope and severity of bone destruction. *Annals of the Rheumatic Diseases*, **2006**, 65, 905-9	2.4	107
55	Therapeutic targets in rheumatoid arthritis: More to come but which one(s) to select?. *Drug Discovery Today Disease Mechanisms*, **2005**, 2, 327-330		1
54	Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. *Arthritis Research*, **2005**, 7, R149-55		53

53	Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. *Annals of the Rheumatic Diseases*, **2005**, 64, 415-8	2.4	38
52	Control and Induction of Autoimmunity by Cytokine and Anti-cytokine Treatments **2005**, 329-345		
51	RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. *Arthritis and Rheumatism*, **2005**, 52, 2307-12		94
50	Lupus et cytokines : compréhension des signes cliniques et identification des cibles thérapeutiques. *Revue Du Rhumatisme (Edition Francaise)*, **2005**, 72, 126-129	0.1	
49	mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. *Journal of Clinical Immunology*, **2005**, 25, 209-14	5.7	56
48	Enhancement of adenovirus-mediated gene delivery to rheumatoid arthritis synoviocytes and synovium by fiber modifications: role of arginine-glycine-aspartic acid (RGD)- and non-RGD-binding integrins. *Journal of Immunology*, **2005**, 175, 7687-98	5.3	24
47	Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. *Annals of the Rheumatic Diseases*, **2005**, 64, 1257-62	2.4	49
46	TNFet polyarthrite rhumatoïde : compréhension du mode d'action et des effets secondaires des inhibiteurs thérapeutiques. *Revue Du Rhumatisme (Edition Francaise)*, **2004**, 71, S14-S21	0.1	
45	IL-17 et polyarthrite rhumatoïde : une nouvelle cible thérapeutique ou juste une autre cytokine ?. *Revue Du Rhumatisme (Edition Francaise)*, **2004**, 71, 171-174	0.1	
44	Paired synovium and lymph nodes from rheumatoid arthritis patients differ in dendritic cell and chemokine expression. *Journal of Pathology*, **2004**, 204, 28-38	9.4	52
43	Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: Interaction with chemokines and Th1 cytokine-producing cells. *Arthritis and Rheumatism*, **2004**, 50, 199-208		105
42	Regulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritis. *Arthritis and Rheumatism*, **2004**, 50, 1800-5		12
41	Inmunopatología de la artritis reumatoide. *EMC - Aparato Locomotor*, **2004**, 37, 1-9	0	
40	Immunopathologie de la polyarthrite rhumatoïde. *EMC - Rhumatologie-Orthopedie*, **2004**, 1, 218-230		4
39	Increased AP-1 and NF-kappaB activation and recruitment with the combination of the proinflammatory cytokines IL-1beta, tumor necrosis factor alpha and IL-17 in rheumatoid synoviocytes. *Arthritis Research*, **2004**, 6, R190-8		58
38	Decreased response to IL-12 and IL-18 of peripheral blood cells in rheumatoid arthritis. *Arthritis Research*, **2004**, 6, R39-R45		18
37	Combination of the pro-inflammatory cytokines IL-1, TNF-alpha and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1 and NF-kappaB in osteoblast-like cells. *Cytokine*, **2004**, 26, 169-77	4	61
36	Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. *American Journal of Pathology*, **2004**, 164, 409-17	5.8	49

35	Peptidylpropyl isomerase B (PPIB): a suitable reference gene for mRNA quantification in peripheral whole blood. *Journal of Biotechnology*, **2004**, 114, 121-4	3.7	65
34	An update on the cytokine network in rheumatoid arthritis. *Current Opinion in Rheumatology*, **2004**, 16, 218-22	5.3	66
33	IL-17 as a contributor to inflammation and destruction in rheumatoid arthritis **2004**, 147-163		1
32	Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. *Journal of Neuroimmunology*, **2003**, 137, 125-33	3.5	82
31	Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. *Arthritis and Rheumatism*, **2003**, 48, 594-601		223
30	Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. *Arthritis and Rheumatism*, **2003**, 48, 631-7		35
29	Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. *Journal of Immunology*, **2002**, 168, 5333-41	5.3	177
28	Anti-interleukin 1alpha autoantibodies. *Annals of the Rheumatic Diseases*, **2002**, 61, 577-9	2.4	10
27	Addition of interleukin 1 (IL1) and IL17 soluble receptors to a tumour necrosis factor alpha soluble receptor more effectively reduces the production of IL6 and macrophage inhibitory protein-3alpha and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation. *Annals of the Rheumatic Diseases*, **2002**, 61, 730-3	2.4	20
26	The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. *Arthritis and Rheumatism*, **2001**, 44, 1293-303		172
25	IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. *Genes and Immunity*, **2001**, 2, 222-8	4.4	104
24	A routine assay for the direct analysis of HLA-DR-related shared epitope and B27 alleles in chronic inflammatory arthritis. *Journal of Immunological Methods*, **2001**, 256, 47-53	2.5	8
23	IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. *Arthritis Research*, **2001**, 3, 168-77		257
22	Potential contribution of IL-17-producing Th(1)cells to defective repair activity in joint inflammation: partial correction with Th(2)-promoting conditions. *Cytokine*, **2001**, 13, 113-8	4	31
21	Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. *Journal of Immunology*, **2001**, 167, 6015-20	5.3	201
20	IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. *Journal of Clinical Investigation*, **2000**, 105, 1697-710	15.9	243
19	Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. *Cytokine*, **2000**, 12, 1092-9	4	235
18	Change in the Th1/Th2 phenotype of memory T-cell clones from rheumatoid arthritis synovium. *Scandinavian Journal of Immunology*, **1999**, 50, 1-9	3.4	51

17	Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. *Arthritis and Rheumatism*, **1999**, 42, 963-70		796
16	Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. *Bone*, **1999**, 24, 381-5	4.7	69
15	IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. *Journal of Immunology*, **1999**, 162, 1246-51	5.3	261
14	Increased production of a Th2 cytokine profile by activated whole blood cells from rheumatoid arthritis patients. *Journal of Clinical Immunology*, **1998**, 18, 399-403	5.7	18
13	Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis: correlations with markers of inflammation and joint destruction. *Arthritis and Rheumatism*, **1998**, 41, 1083-9		50
12	Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. *Journal of Immunology*, **1998**, 161, 409-14	5.3	318
11	Cytokine-induced autoimmune disorders. *Drug Safety*, **1997**, 17, 93-104	5.1	40
10	High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: a follow-up study. *Scandinavian Journal of Immunology*, **1997**, 46, 413-8	3.4	40
9	Th1/Th2 cytokine balance in arthritis. *Arthritis and Rheumatism*, **1997**, 40, 2105-15		234
8	Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. *Molecular Immunology*, **1996**, 33, 649-58	4.3	19
7	Increased incidence of neutralizing autoantibodies against interleukin-1 alpha (IL-1 alpha) in nondestructive chronic polyarthritis. *Journal of Clinical Immunology*, **1996**, 16, 283-90	5.7	22
6	Interleukin 4, but not interleukin 10, regulates the production of inflammation mediators by rheumatoid synoviocytes. *Cytokine*, **1995**, 7, 176-83	4	30
5	The ability of synoviocytes to support terminal differentiation of activated B cells may explain plasma cell accumulation in rheumatoid synovium. *Journal of Clinical Investigation*, **1995**, 95, 456-63	15.9	99
4	Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. *Arthritis and Rheumatism*, **1994**, 37, 1715-22		86
3	Interferon gamma inhibits interleukin 10 production by monocytes. *Journal of Experimental Medicine*, **1993**, 177, 523-7	16.6	254
2	Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0-like) cytokine patterns. *Scandinavian Journal of Immunology*, **1993**, 38, 75-82	3.4	127
1	Low levels of interleukin-4 and high levels of transforming growth factor beta in rheumatoid synovitis. *Arthritis and Rheumatism*, **1990**, 33, 1180-7		138